Author Archives: Patricia Inacio PhD

Ankylosing spondylitis genes, potential treatments ID’d: Study

Genes involved in ankylosing spondylitis (AS) as well as potential new therapies have been identified through a computer-based analysis, according to a study. The findings “contribute to our understanding of the molecular mechanisms underlying the onset and progression of AS. They also provide candidate targets for the diagnosis and…

Erectile dysfunction may be twice as common in men with AS

Men with ankylosing spondylitis (AS) are at a higher risk of erectile dysfunction than are healthy men in the general population, according to a meta-analysis of data covering nearly 400 people with AS. “Conflicting results” are evident across the reviewed work, however, and “more high-quality studies are needed in…

FDA approves higher concentration of Hyrimoz, Humira biosimilar

A high concentration formulation of Sandoz’s biosimilar Hyrimoz (adalimumab-adaz) has been approved by the U.S. Food and Drug Administration (FDA) to treat ankylosing spondylitis (AS) and other conditions. The new citrate-free formulation (100 mg/mL) is expected to be available on July 1, according to Sandoz. It’s approved for seven…

NIH Funds Project to Speed Diagnosis of Rare Diseases

The diagnosis of rare diseases such as akylosing spondylitis (AS) is complex and often delayed. A partnership between U.S. researchers aims to use artificial intelligence to develop a software to diagnose rare diseases sooner. The four-year project, led by researchers at the University of Florida Health and the Perelman School…

New Citrate-free Taltz Becoming Available for AS Patients in US

A new and citrate-free formulation of Taltz (ixekizumab) is being made available to treat adults with active ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA) patients who have signs of inflammation. Symptoms of nr-axSpA are similar to AS, but without X-ray evidence of inflammation. This formulation of the Eli Lilly therapy was…